Pelanserin
Names
Preferred IUPAC name
3-[3-(4-Phenylpiperazin-1-yl)propyl]quinazoline-2,4(1H,3H)-dione
Identifiers
3D model (JSmol)
ChemSpider
UNII
  • InChI=1S/C21H24N4O2/c26-20-18-9-4-5-10-19(18)22-21(27)25(20)12-6-11-23-13-15-24(16-14-23)17-7-2-1-3-8-17/h1-5,7-10H,6,11-16H2,(H,22,27)
    Key: WPKPLSFHHBBLRY-UHFFFAOYSA-N
  • InChI=1/C21H24N4O2/c26-20-18-9-4-5-10-19(18)22-21(27)25(20)12-6-11-23-13-15-24(16-14-23)17-7-2-1-3-8-17/h1-5,7-10H,6,11-16H2,(H,22,27)
    Key: WPKPLSFHHBBLRY-UHFFFAOYAV
  • C1CN(CCN1CCCN2C(=O)C3=CC=CC=C3NC2=O)C4=CC=CC=C4
Properties
C21H24N4O2
Molar mass 364.449 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references
This article provides insufficient context for those unfamiliar with the subject. Please help improve the article by providing more context for the reader. (March 2021) (Learn how and when to remove this template message)

Pelanserin is an antagonist of the 5-HT2 and α1-adrenergic receptors.[1]

References

  1. ^ Villalobos-Molina, R; Ibarra, M; Hong, E (1995). "The 5-HT2 receptor antagonist, pelanserin, inhibits alpha 1-adrenoceptor-mediated vasoconstriction in vitro". European Journal of Pharmacology. 277 (2–3): 181–5. doi:10.1016/0014-2999(95)00074-u. PMID 7493607.